We haven’t heard anything about this indication for quite some time. I thought that the placebo arm were to be treated?
Excitement was brewing at the time but all is quiet. Did Any Lightners deflection to a competitor put a hold on proceedings?
While Direct Biologics power on with their trial, are we left doing nothing about it?
Or is it possible that MSB have a strategy in place to extend Rem-l to this indication once approved for GVHD to bring in some $$ to help fund further trials?
Does anyone know if a label extension is possible for UC and Crohns?
We haven’t heard anything about this indication for quite some...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.51M | 10.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17804 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 230637 | 5 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |